Biomarin Pharmaceutical (BMRN) Non-Current Deffered Revenue (2010 - 2012)

Biomarin Pharmaceutical has disclosed Non-Current Deffered Revenue across 3 years of filings, most recently posting $13.1 million for Q3 2012.

• Quarterly Non-Current Deffered Revenue rose 62.15% year-over-year to $13.1 million in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $13.1 million (up 62.15% YoY) and the FY2011 annual result came in at $8.8 million, up 816.2% from the prior year.
• Non-Current Deffered Revenue grew to $13.1 million in Q3 2012, from $4.2 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $13.1 million in Q3 2012 and troughed at $957000.0 in Q4 2010.
• A 3-year average of $5.4 million and a median of $4.2 million in 2012 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2011 — Non-Current Deffered Revenue surged 816.2% — and 2012, when it jumped 62.15%.
• Tracing BMRN's Non-Current Deffered Revenue over 3 years: stood at $957000.0 in 2010, then jumped by 816.2% to $8.8 million in 2011, then soared by 49.79% to $13.1 million in 2012.
• Business Quant data shows BMRN's Non-Current Deffered Revenue at $13.1 million in Q3 2012, $4.2 million in Q2 2012, and $1.9 million in Q1 2012.